84 result(s) found
Are Consumer Staples Stocks Lagging Ahold (ADRNY) This Year?
https://www.zacks.com/stock/news/2211424/are-consumer-staples-stocks-lagging-ahold-adrny-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2211424
Jan 17, 2024 - Here is how Ahold NV (ADRNY) and Britvic PLC Sponsored ADR (BTVCY) have performed compared to their sector so far this year.
0
These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High
https://www.zacks.com/commentary/2211005/these-stocks-are-showing-relative-strength-as-s-p-500-stalls-near-record-high?cid=CS-ZC-FT-investment_ideas-2211005
Jan 16, 2024 - As investors, our job isn't to predict an unknowable future.
0
Novartis said to have backed away from a deal for Cytokinetics
https://seekingalpha.com/news/4054454-novartis-backs-away-cytokinetics-deal?source=feed_sector_healthcare
Jan 11, 2024 - Novartis (NVS) withdraws bid to acquire Cytokinetics, causing a drop in the biotech company's shares. Read more here.
0
The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group
https://www.zacks.com/stock/news/2206930/the-zacks-analyst-blog-highlights-merck-salesforce-philip-morris-international-novartis-and-cme-group?cid=CS-ZC-FT-press_releases-2206930
Jan 08, 2024 - Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.
0
Top Analyst Reports for Merck, Salesforce & Philip Morris
https://www.zacks.com/commentary/2206306/top-analyst-reports-for-merck-salesforce-philip-morris?cid=CS-ZC-FT-research_daily-2206306
Jan 05, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
0
NVS or LLY: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2206412/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2206412
Jan 05, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option?
0
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
https://www.zacks.com/stock/news/2205605/biotech-stock-roundup-vygr-gains-from-nvs-deal-agio-up-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2205605
Jan 04, 2024 - Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
0
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
https://www.zacks.com/stock/news/2205112/voyager-vygr-gains-on-gene-therapy-deal-with-novartis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205112
Jan 03, 2024 - Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
0
Arcadis NV (ARCAY) Is a Great Choice for 'Trend' Investors, Here's Why
https://www.zacks.com/stock/news/2204413/arcadis-nv-arcay-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2204413
Jan 02, 2024 - If you are looking for stocks that are well positioned to maintain their recent uptrend, Arcadis NV (ARCAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
0
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
https://www.zacks.com/stock/news/2200609/roche-s-rhhby-sbla-for-xolair-gets-fda-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200609
Dec 20, 2023 - The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.
0